Medicare Advantage Denials Raise Concerns
A recent investigation has intensified worries that Medicare Advantage (MA) insurers might be denying necessary care to seniors in order to boost profits. The Department of Health’s Office of Inspector General (HHS OIG) released reports indicating alarmingly high denial rates for post-acute care, particularly from major insurers like UnitedHealth, Humana, and CVS, which reject prior authorization requests at much higher rates than their smaller counterparts.
Interestingly, many of these denials were overturned upon appeal, hinting that they perhaps should have been approved initially, according to the watchdog agency.
Experts are increasingly voicing that improper claim denials are a growing concern, especially as the MA program continues to expand. Currently, about 51% of Medicare beneficiaries are enrolled in MA, and that number might climb to 56% within the next decade, based on government projections. This rising trend means that millions of older Americans are facing hurdles to accessing necessary care.
Yet, insurance groups are disputing the findings, labeling the study as skewed and lacking in current relevance.
High Denial Rates for Post-Acute Care
The landscape for Medicare Advantage is becoming increasingly complex as the government allocates vast sums to private insurers to manage senior care. Critics argue that costs associated with MA are higher than those of traditional Medicare, largely due to widespread manipulations of the payment framework by insurers aiming to maximize their profits. This includes the ability to restrict medical services in ways that traditional Medicare does not.
According to previous research, MA insurers are often overly stringent with prior authorizations. The latest reports hone in on a specific concern: post-acute care after hospital stays, which includes referrals to long-term care facilities and rehabilitation centers crucial for recovery after serious health events.
The HHS OIG’s analysis covered 19 MA insurers, representing 29.3 million beneficiaries in 2024, accounting for roughly 86% of individuals enrolled in the program at that time. The findings showed that insurance companies were largely denying necessary claims. Notably, around two-thirds of requests for admission to long-term care hospitals faced denial, with similar trends in requests for inpatient rehabilitation.
The major players—UnitedHealth, Humana, and CVS—had the highest rates of denial, rejecting over 70% of long-term care hospital requests and more than half of those for rehabilitation facilities.
Further detailing these trends, the HHS OIG revealed that 12% of overall admissions to skilled nursing facilities were denied, with denial rates fluctuating from 0.4% to 23%. Again, the largest three insurers stood out with the highest refusal rates.
Critical Issues Surrounding Appeals
What’s particularly troubling is the low number of appeals filed against these denials. Only about a third of denied long-term care admission applications were appealed, and even fewer for skilled nursing claims. However, when beneficiaries did appeal, MA insurers overturned a significant percentage of denials, indicating that many initially denied requests were, in fact, medically necessary.
The lengthy appeal process often forces patients to remain in hospitals longer, leading to additional medical expenses and potentially compromising their health further. Delays in receiving care can exacerbate health issues, making a compelling case for refining the existing system.
The high rates of denial across the board prompt concerns that Medicare Advantage beneficiaries might be neglected when it comes to accessing essential services. The scrutiny on UnitedHealth, Humana, and CVS has only intensified, especially after a Senate report highlighted how the adoption of algorithmic tools for claims review led to skyrocketing denial rates.
Insurance Companies’ Response
Insurers do acknowledge the need to streamline processes while defending prior authorization as a necessary tool to avoid unnecessary procedures. Yet, they claim that the HHS OIG’s findings lack important context, arguing that many denials stem from clerical errors made by healthcare providers. They also caution that post-acute care can be wasteful, justifying the need for authorizations.
Some industry leaders assert that meaningful changes to minimize prior authorizations have already taken place, emphasizing that millions of these reviews have been eliminated recently across markets.
While the high rates of denial require urgent attention, the HHS OIG has called for more extensive data collection to assist regulators in identifying potential fraud. This challenge remains paramount as the Medicare Advantage population continues to grow.
In conclusion, as concerns rise about the effectiveness and fairness of care under Medicare Advantage, the importance of delivering promised value to beneficiaries only becomes clearer with each new report.
